Literature DB >> 8424321

Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6.

A Llerena1, G Edman, J Cobaleda, J Benítez, D Schalling, L Bertilsson.   

Abstract

We administered the Karolinska Scales of Personality to 225 healthy subjects in Spain selected from a group of 925 individuals previously phenotyped with regard to their capacity to hydroxylate debrisoquine. A significant relationship was found between the scores in as many as 4 of the 15 subscales (psychic anxiety, psychasthenia, inhibition of aggression and socialization) and the debrisoquine hydroxylation capacity. Poor metabolizers were more anxiety-prone and less successfully socialized than extensive metabolizers of debrisoquine. This and a previous study among subjects in Sweden suggest that there may be a relationship between personality and the activity of the enzyme hydroxylating debrisoquine (cytochrome P4502D6). This polymorphic enzyme may have an endogenous neuroactive substrate or product, such as a biogenic neurotransmitter amine.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8424321     DOI: 10.1111/j.1600-0447.1993.tb03325.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  24 in total

Review 1.  Phenotyping of Human CYP450 Enzymes by Endobiotics: Current Knowledge and Methodological Approaches.

Authors:  Gaëlle Magliocco; Aurélien Thomas; Jules Desmeules; Youssef Daali
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

2.  No association between CYP2D6 polymorphisms and personality trait in Japanese.

Authors:  Kumiko Iwashima; Norio Yasui-Furukori; Ayako Kaneda; Manabu Saito; Taku Nakagami; Yasushi Sato; Sunao Kaneko
Journal:  Br J Clin Pharmacol       Date:  2007-02-23       Impact factor: 4.335

3.  Brain drug-metabolizing cytochrome P450 enzymes are active in vivo, demonstrated by mechanism-based enzyme inhibition.

Authors:  Sharon Miksys; Rachel F Tyndale
Journal:  Neuropsychopharmacology       Date:  2008-07-30       Impact factor: 7.853

Review 4.  CYP2D6 variation, behaviour and psychopathology: implications for pharmacogenomics-guided clinical trials.

Authors:  Eva M Peñas-Lledó; Adrián Llerena
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

5.  Anatomical distribution of NADPH-cytochrome P450 reductase and cytochrome P4502D forms in rat brain: effects of xenobiotics and sex steroids.

Authors:  A F Bergh; H W Strobel
Journal:  Mol Cell Biochem       Date:  1996-09-06       Impact factor: 3.396

Review 6.  Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype.

Authors:  A Llerena; J Cobaleda; C Martínez; J Benítez
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Apr-Jun       Impact factor: 2.441

7.  Sex hormones regulate cerebral drug metabolism via brain miRNAs: down-regulation of brain CYP2D by androgens reduces the analgesic effects of tramadol.

Authors:  Jie Li; Mengmeng Xie; Xiaoshuang Wang; Xiufang Ouyang; Yu Wan; Guicheng Dong; Zheqiong Yang; Jing Yang; Jiang Yue
Journal:  Br J Pharmacol       Date:  2015-08-26       Impact factor: 8.739

Review 8.  Cytochrome P450-mediated drug metabolism in the brain.

Authors:  Sharon Miksys; Rachel F Tyndale
Journal:  J Psychiatry Neurosci       Date:  2013-05       Impact factor: 6.186

9.  Ethanol self-administration and nicotine treatment increase brain levels of CYP2D in African green monkeys.

Authors:  R T Miller; S Miksys; E Hoffmann; R F Tyndale
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

10.  The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6.

Authors:  Natasha T Snider; Matthew J Sikora; Chitra Sridar; Thomas J Feuerstein; James M Rae; Paul F Hollenberg
Journal:  J Pharmacol Exp Ther       Date:  2008-08-12       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.